Cencora (COR) investor relations material

Key financial guidance and confidence

• Leadership expressed strong confidence in both full-year and long-term guidance, reaffirming EPS guidance of $17.65–$17.90 and free cash flow guidance of $3 billion for the fiscal year.

• $1 billion in share repurchases is planned by year-end, with opportunistic buybacks prioritized due to recent share price pullback.

• Guidance increase was attributed to asset held for sale accounting in the MWI business, with utilization trends in specialty as the main variable for performance within the range.

• Capital deployment priorities remain CapEx, strategic M&A, share repurchases, and a growing dividend.

U.S. Healthcare Solutions performance and outlook

• Organic AOI growth normalized to 9% after adjusting for $10M COVID and $10M weather headwinds.

• Growth expected to accelerate in the second half due to lapping oncology customer loss, ramping OneOncology contributions, and easier OpEx comps.

• Utilization trends, especially in specialty, are the key driver for guidance range outcomes.

• Biosimilar transitions (e.g., STELARA, HUMIRA) impact revenue but have minimal effect on operating income.

M&A, integration, and pipeline

• Integration of RCA and OneOncology is progressing well, with synergies and teamwork exceeding expectations.

• Both platforms have strong pipelines for tuck-in acquisitions, especially in retina and oncology, focusing on smaller, less sophisticated practices.

• Recent retina-focused deals, such as the EyeSouth carve-out, exemplify the tuck-in strategy.

• Acquisitions have historically driven strong operating income growth and allowed physicians to maintain clinical independence.